185 related articles for article (PubMed ID: 35172108)
1. Past, Present, and Future of Therapies for Pituitary Neuroendocrine Tumors: Need for Omics and Drug Repositioning Guidance.
Aydin B; Yildirim E; Erdogan O; Arga KY; Yilmaz BK; Bozkurt SU; Bayrakli F; Turanli B
OMICS; 2022 Mar; 26(3):115-129. PubMed ID: 35172108
[TBL] [Abstract][Full Text] [Related]
2. Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.
Aydin B; Beklen H; Arga KY; Bayrakli F; Turanli B
J Endocrinol Invest; 2023 Apr; 46(4):727-747. PubMed ID: 36306107
[TBL] [Abstract][Full Text] [Related]
3. Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.
Aydin B; Caliskan A; Arga KY
EPMA J; 2021 Sep; 12(3):383-401. PubMed ID: 34567287
[TBL] [Abstract][Full Text] [Related]
4. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
[TBL] [Abstract][Full Text] [Related]
5. Aggressive pituitary tumors (PitNETs).
Nishioka H
Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
[TBL] [Abstract][Full Text] [Related]
6. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
[TBL] [Abstract][Full Text] [Related]
7. Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.
Wang L; Wei C; Wang Y; Huang N; Zhang T; Dai Y; Xue L; Lin S; Wu ZB
Front Endocrinol (Lausanne); 2023; 14():1149997. PubMed ID: 37534217
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.
Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y
Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171
[TBL] [Abstract][Full Text] [Related]
9. Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.
Serioli S; Agostini L; Pietrantoni A; Valeri F; Costanza F; Chiloiro S; Buffoli B; Piazza A; Poliani PL; Peris-Celda M; Iavarone F; Gaudino S; Gessi M; Schinzari G; Mattogno PP; Giampietro A; De Marinis L; Pontecorvi A; Fontanella MM; Lauretti L; Rindi G; Olivi A; Bianchi A; Doglietto F
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958702
[TBL] [Abstract][Full Text] [Related]
10. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
Luo P; Zhang L; Yang L; An Z; Tan H
Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
[TBL] [Abstract][Full Text] [Related]
11. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
[TBL] [Abstract][Full Text] [Related]
12. Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.
Asa SL
Endocr Pathol; 2021 Jun; 32(2):222-227. PubMed ID: 33866514
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
Wen S; Li J; Yang J; Li B; Li N; Zhan X
Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
[TBL] [Abstract][Full Text] [Related]
14. Aggressive nonfunctioning pituitary neuroendocrine tumors.
Portovedo S; Neto LV; Soares P; Carvalho DP; Takiya CM; Miranda-Alves L
Brain Tumor Pathol; 2022 Oct; 39(4):183-199. PubMed ID: 35725837
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
[TBL] [Abstract][Full Text] [Related]
16. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
17. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
[TBL] [Abstract][Full Text] [Related]
18. Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients.
Guaraldi F; Morandi L; Zoli M; Mazzatenta D; Righi A; Evangelisti S; Ambrosi F; Tonon C; Giannini C; Lloyd RV; Asioli S
Clin Endocrinol (Oxf); 2022 Dec; 97(6):763-772. PubMed ID: 36161330
[TBL] [Abstract][Full Text] [Related]
19. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.
Zhou Y; Zhang A; Fang C; Yuan L; Shao A; Xu Y; Zhou D
CNS Neurosci Ther; 2023 Oct; 29(10):2744-2759. PubMed ID: 37341156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
